Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-concept clinical data for its next-generation, half-life extended TCR Bispecific molecule, TCER IMA401 (MAGEA4/8), will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 on Monday, September 16, 2024 at 11:25 CEST.
2024年7月18日,德國腫瘤免疫治療生物製品公司immatics(納斯達克股票代碼:IMTX,"immatics")與美國德克薩斯州的休斯頓市(Houston)宣佈,其下一代半衰期延長的TCR雙特異性分子,TCER IMA401(MAGEA4/8),的首個概念證明臨床數據將於2024年9月16日星期一中歐夏令時11:25在2024年歐洲醫學腫瘤學會(ESMO)大會上進行口頭報告。
Full abstracts will be available on the ESMO website on Monday, September 9, 2024, at 00:05 CEST.
2024年9月9日中歐夏令時00:05,具體摘要可以在歐洲醫學腫瘤學會(ESMO)的網站上查看。
Oral presentation
口頭報告
Date / Time: September 16, 2024 / 11:25 CEST
Session: Investigational Immunotherapy
Title: Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation
Presenting author: Martin Wermke, MD (University Hospital Dresden, Germany)
Room: Granada Auditorium - Hall 6
日期/時間:2024年9月16日/中歐夏令時11:25
會議:調查性免疫療法
題目:TCER IMA401的初始安全性、藥代動力學和抗腫瘤活性數據:一項I期逐步增加劑量的MAGEA4/8定向半衰期延長的TCR雙特異性試驗研究
報告作者:Martin Wermke, MD (德國德累斯頓大學醫院)
地點:格拉納達禮堂 - 6號廳
About IMA401
關於IMA401
IMA401 is Immatics' most advanced TCER molecule that targets an HLA-A*02-presented (human leukocyte antigen) peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 ("MAGEA4/8"). The MAGEA4/8 peptide has been identified and validated by Immatics' proprietary mass spectrometry-based target discovery platform XPRESIDENT and is presented at a 5-fold higher copy number per tumor cell than the MAGEA4 peptide targeted in other clinical trials. Following preclinical proof-of-concept data, including complete remissions of transplanted human-derived tumors in xenograft mouse models, the Phase 1 trial investigates IMA401 in patients with tumors of high MAGEA4/8 prevalence, such as squamous non-small cell lung carcinoma (sqNSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian carcinomas, as well as melanoma, sarcoma subtypes and other solid cancer types.
IMA401是Immatics最先進的TCER分子,針對HLA-A*02介導(人類白細胞抗原)的多肽肽段,來自兩種不同的癌相關蛋白,黑色素瘤相關抗原4和/或8("MAGEA4/8")。在其他臨床試驗中,MAGEA4多肽的靶向量已被證實。使用Immatics專有的基於質譜的XPRESIDENT靶點發現平台驗證的MAGEA4/8多肽片段,其在腫瘤細胞中以比MAGEA4多肽高5倍的複製數呈現。在完成移植的人源性腫瘤在移植的小鼠模型中的全部緩解等預臨床概念證明數據之後,I期試驗研究IMA401在具有高MAGEA4/8流行病學的腫瘤患者中,如鱗狀非小細胞肺癌(sqNSCLC)、小細胞肺癌(SCLC)、頭頸部鱗狀細胞癌(HNSCC)、膀胱、子宮、食管和卵巢癌,以及黑色素瘤、肉瘤亞型和其他實體癌類型。
About TCER
關於TCER
Immatics' next-generation half-life extended TCER molecules are antibody-like "off-the-shelf" biologics that leverage the body's immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. The design of the TCER molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells' intrinsic specificity. Immatics proprietary biologics are engineered with two binding regions: a TCR domain and a T cell recruiter domain. The TCER format is designed to maximize efficacy while minimizing toxicities in patients. It contains a high-affinity TCR domain that is designed to bind specifically to the cancer target peptide on the cell surface presented by an HLA molecule. The antibody-derived, low-affinity T cell recruiter domain is directed against the TCR/CD3 complex and recruits a patient's T cells to the tumor to attack the cancer cells. With a low-affinity recruiter aiming for optimized biodistribution and enrichment of the molecule at the tumor site instead of the periphery, TCER are engineered to reduce the occurrence of immune-related adverse events, such as cytokine release syndrome. In addition, the TCER format consists of an Fc-part conferring half-life extension, stability, and manufacturability. TCER are "off-the-shelf" biologics and thus immediately available for patient treatment. They can be distributed through standard pharmaceutical supply chains and provide the opportunity to reach a large patient population without the need for specialized medical centers.
Immatics的下一代半衰期延長的TCER分子是類抗體的"現成"生物學品,通過重定向和激活t細胞對錶達特定腫瘤靶點的癌細胞發揮免疫系統的作用。TCER分子的設計使得人體內的任何t細胞都能攻擊腫瘤,無論t細胞的內在特異性如何。Immatics的專有生物學制品是通過兩個結合區域進行工程化設計的:一個TCR區域和一個t細胞招募區域。TCER格式的設計旨在在患者中最大化功效,同時將毒性降至最低。它包含高親和力的TCR區域,專門設計用於與細胞表面的腫瘤靶點多肽結合,並通過HLA分子呈現。低親和力的源自抗體的t細胞招募區域,針對TCR/CD3複合物並招募患者的t細胞攻擊癌細胞。乍看想要在腫瘤靶區域而不是周邊體內增強招募的低親和力招募者,TCER被設計爲減少免疫相關不良事件(如細胞因子釋放綜合徵)的發生。此外,TCER格式由一個Fc部分組成,從而實現半衰期延長、穩定性和可製造性。TCER是"現成"的生物學品,因此可立即用於患者治療。它們可以通過標準的藥品供應鏈分配,併爲達到不需要專業醫療中心、大量患者的機會提供了可能。
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
關於Immatics
Immatics通過爲癌症免疫治療發現真正的靶點和開發正確的t細胞受體,旨在實現對這些靶點的強大和特異性t細胞應答。這種深刻的專業知識是我們的養分,是我們的細胞治療和TCR特異性治療以及我們與全球製藥業領導者的合作伙伴關係的基礎。我們致力於釋放t細胞的威力,爲患者在與癌症的鬥爭中開闢新的道路。
Immatics intends to use its website as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.
Immatics有意使用其網站作爲披露非公開信息的手段。您也可以在X、Instagram和LinkedIn上關注我們以獲得定期更新。
For more information, please contact:
更多信息,請聯繫:
Media | |
Trophic Communications | |
Phone: +49 171 3512733 | |
immatics@trophic.eu |
媒體 | |
Trophic Communications | |
電話:+49 171 3512733 | |
電子郵箱:immatics@trophic.eu |
Immatics N.V. | |
Jordan Silverstein | |
Head of Strategy | |
Phone: +1 346 319-3325 | |
InvestorRelations@immatics.com |
Immatics N.V. | |
Jordan Silverstein | |
策略主管 | |
電話:+1 346 319-3325 | |
投資者關係:investorrelations@immatics.com |
Attachment
附件
- PDF Version
- PDF版本